332 related articles for article (PubMed ID: 35450523)
1. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
[TBL] [Abstract][Full Text] [Related]
2. Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer's pathologies?
Manoharan SD; Abdul Hamid H; Md Hashim NF; Cheema MS; Chiroma SM; Mustapha M; Mehat MZ
Brain Res; 2024 Apr; 1829():148793. PubMed ID: 38309553
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
5. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A.
Li L; Liu Z; Liu J; Tai X; Hu X; Liu X; Wu Z; Zhang G; Shi M; Zhao G
Neurobiol Dis; 2013 Jun; 54():320-8. PubMed ID: 23321003
[TBL] [Abstract][Full Text] [Related]
7. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
[TBL] [Abstract][Full Text] [Related]
8. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation.
Resende R; Ferreiro E; Pereira C; Oliveira CR
J Neurosci Res; 2008 Jul; 86(9):2091-9. PubMed ID: 18335524
[TBL] [Abstract][Full Text] [Related]
9. Gypenoside IX restores Akt/GSK-3β pathway and alleviates Alzheimer's disease-like neuropathology and cognitive deficits.
Lei L; Luo Y; Kang D; Yang F; Meng D; Wang JZ; Liu R; Wang X; Li HL
Aging (Albany NY); 2023 Dec; 15(23):14172-14191. PubMed ID: 38095632
[TBL] [Abstract][Full Text] [Related]
10. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
[TBL] [Abstract][Full Text] [Related]
11. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
[TBL] [Abstract][Full Text] [Related]
12. Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.
DaRocha-Souto B; Coma M; Pérez-Nievas BG; Scotton TC; Siao M; Sánchez-Ferrer P; Hashimoto T; Fan Z; Hudry E; Barroeta I; Serenó L; Rodríguez M; Sánchez MB; Hyman BT; Gómez-Isla T
Neurobiol Dis; 2012 Jan; 45(1):425-37. PubMed ID: 21945540
[TBL] [Abstract][Full Text] [Related]
13. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
Arafa RK; Elghazawy NH
Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
[TBL] [Abstract][Full Text] [Related]
14. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
15. Beyond Amyloid: A Machine Learning-Driven Approach Reveals Properties of Potent GSK-3β Inhibitors Targeting Neurofibrillary Tangles.
Nwadiugwu M; Onwuekwe I; Ezeanolue E; Deng H
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473895
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives.
Li Z; Yin B; Zhang S; Lan Z; Zhang L
Eur J Med Chem; 2023 Dec; 261():115817. PubMed ID: 37722288
[TBL] [Abstract][Full Text] [Related]
17. NPD1 Enhances Autophagy and Reduces Hyperphosphorylated Tau and Amyloid-β42 by Inhibiting GSK3β Activation in N2a/APP695swe Cells.
Dai S; Zhou F; Sun J; Li Y
J Alzheimers Dis; 2021; 84(2):869-881. PubMed ID: 34602482
[TBL] [Abstract][Full Text] [Related]
18. A Unique GSK-3β inhibitor B10 Has a Direct Effect on Aβ, Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth.
Shi XL; Yan N; Cui YJ; Liu ZP
Cells; 2020 Mar; 9(3):. PubMed ID: 32155989
[TBL] [Abstract][Full Text] [Related]
19. Combination of PKCε Activation and PTP1B Inhibition Effectively Suppresses Aβ-Induced GSK-3β Activation and Tau Phosphorylation.
Kanno T; Tsuchiya A; Tanaka A; Nishizaki T
Mol Neurobiol; 2016 Sep; 53(7):4787-97. PubMed ID: 26328540
[TBL] [Abstract][Full Text] [Related]
20. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
